fotemustine has been researched along with Central Nervous System Neoplasm in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, Y; Duan, L; Fu, X; Li, L; Li, X; Li, Z; Nan, F; Sun, Z; Tian, L; Wang, X; Wu, J; Yan, J; Yu, H; Zhang, L; Zhang, M; Zhang, X | 1 |
| Chang, Y; Fu, XR; Han, LJ; Li, L; Li, X; Ma, W; Sun, ZC; Wang, XH; Wu, JJ; Zhang, L; Zhang, MZ; Zhang, XD | 1 |
| Dargenio, M; Di Renzo, N; Forese, P; Matera, R; Pennese, E; Vergine, C | 1 |
| Codacci-Pisanelli, G; Della Rocca, C; Frati, L; Gulino, A; Lo Russo, G; Miele, E; Miscusi, M; Papa, A; Petrozza, V; Spinelli, GP; Tomao, S | 1 |
| Fazeny-Dörner, B; Mader, RM; Marosi, C; Piribauer, M; Rizovski, B; Stögermaier, B | 1 |
| Berille, J; Bizzari, JP; Cerrina, ML; Douillard, JY; Gouva, S; Grandgirard, A; Le Chevalier, T; Monnier, A; Pujol, JL; Rivière, A | 1 |
1 review(s) available for fotemustine and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Chemotherapy and target therapy in the management of adult high- grade gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Central Nervous System Neoplasms; Cetuximab; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Nitrosourea Compounds; Organophosphorus Compounds; Promoter Regions, Genetic; Quinazolines; Temozolomide; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins | 2012 |
3 trial(s) available for fotemustine and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Central Nervous System Neoplasms; Cytarabine; Dexamethasone; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Proto-Oncogene Proteins c-bcl-6; Teniposide; Treatment Outcome; Young Adult | 2018 |
Preliminary study on pharmacokinetics of dacarbazine and fotemustine in glioblastoma multiforme patients does not indicate gender-specific differences.
Topics: Adult; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Female; Glioblastoma; Humans; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Sex Factors | 2004 |
Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Prognosis; Quality of Life; Survival Analysis; Time Factors | 1994 |
2 other study(ies) available for fotemustine and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Fotemustine, teniposide and dexamethasone in treating patients with CNS lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Dexamethasone; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Radiotherapy, Adjuvant; Teniposide; Young Adult | 2014 |
Complete response induced by fotemustine given as single agent in a patient with primary central nervous system non-Hodgkin aggressive lymphoma relapsed after high-dose chemotherapy and autologous stem cell support.
Topics: Adult; Antineoplastic Agents; Central Nervous System Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Therapy; Humans; Lymphoma, Non-Hodgkin; Male; Nitrosourea Compounds; Organophosphorus Compounds; Recurrence; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2011 |